Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02670785 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy
A Phase 2 study of Menopause and Dyspareunia, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 2
- Development phase
- 203
- Enrollment target
- 20
- Study locations
NCT02670785 is a Phase 2 study of Menopause and Dyspareunia that has completed, run by Warner Chilcott. The registered enrollment target is 203 participants, below the 9,390-participant average among 54 other Menopause trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT02670785, a Phase 2 study of Menopause and Dyspareunia, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 203 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will access the safety and efficacy of three doses of estradiol vaginal capsules in postmenopausal women with vulvovaginal atrophy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Estradiol Vaginal Capsule (EVC)
Study Locations (20)
Florida
- Women's Medical Research Group, LLC - Clearwater
- Radiant Research, Inc. - Pinellas Park
- Comprehensive Clinical Trials, LLC - West Palm Beach
North Carolina
- Carolina Women's Research and Wellness Center - Durham
- Hawthorne Medical Research, Inc. - Winston-Salem
Ohio
- Rapid Medical Research, Inc. - Cleveland
- Women's Health Research - Columbus
Texas
- Radiant Research, Inc. - Dallas
- Radiant Research, Inc. - San Antonio
Washington
- Seattle Women's Health, Research, Gynecology - Seattle
- North Spokane Women's Clinic - Spokane
Arizona
- Visions Clinical Research-Tucson - Tucson
California
- Genesis Center for Clinical Research - San Diego
Connecticut
- Coastal Connecticut Research, LLC - New London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2016-02-15 |
| Est. Completion | 2016-11-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02670785
The ClinicalTrials.gov registry entry for NCT02670785 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 9,390-participant average among 54 other Menopause trials with a reported enrollment target (98% lower). The listed sponsor is Warner Chilcott, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Menopause appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02670785 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, North Carolina, Ohio.
Frequently Asked Questions
What is clinical trial NCT02670785 about?
NCT02670785 is a clinical study titled "A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy". This study will access the safety and efficacy of three doses of estradiol vaginal capsules in postmenopausal women with vulvovaginal atrophy.
What is the current status of trial NCT02670785?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 203 participants. The study started on 2016-02-15. Estimated completion is 2016-11-14.
What conditions does trial NCT02670785 study?
This clinical trial studies the following conditions: Menopause, Dyspareunia, Vulvovaginal Atrophy.
What interventions are being tested in trial NCT02670785?
The interventions under investigation include: Placebo (DRUG), Estradiol Vaginal Capsule (EVC) (DRUG).
Who is sponsoring clinical trial NCT02670785?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02670785 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Menopause
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Anabolic Effect of Testosterone on Pelvic Floor Muscles
RECRUITING · Phase 2
-
Effects of Hemp-Derived Cannabinoids on Menopause Symptoms
RECRUITING · Phase 2
-
Impact of Cannabinoids on Menopause Symptoms
RECRUITING · Phase 2
-
PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition
ACTIVE NOT RECRUITING · Phase 2
-
Hormone Replacement in Menopausal Women With Epilepsy
COMPLETED · Phase 2
-
Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.